Related Experiment Video
Updated: Feb 27, 2026
11:49
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
16.7K
Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants
S Chandran1, Q Tang2,3, M Sarwal2
1Department of Medicine, University of California, San Francisco, CA.
Summary
Regulatory T cell (Treg) therapy is a safe and feasible treatment for subclinical inflammation in kidney transplant recipients. This pilot study shows Treg infusion is well-tolerated, paving the way for future efficacy trials.
Area of Science:
- Immunology
- Nephrology
- Cell Therapy
Background:
- Subclinical inflammation in kidney transplants can lead to fibrosis and dysfunction.
- Regulatory T cells (Tregs) show potential in reversing inflammation in preclinical models.
Purpose of the Study:
- To assess the safety and feasibility of autologous Treg cell therapy in kidney transplant recipients with subclinical inflammation.
- To track the persistence and stability of infused Tregs in patients undergoing immunosuppression.
Main Methods:
- A pilot trial involving three kidney transplant recipients with subclinical inflammation.
- Purification and polyclonal expansion of autologous Tregs ex vivo.
- Single infusion of expanded Tregs and monitoring via biopsies and urinary biomarkers.
Main Results:
- Successful manufacturing of nearly 1 × 10^9 Tregs per patient.
- No infusion reactions or serious therapy-related adverse events observed.
- Infused Tregs showed persistence and stability comparable to non-immunosuppressed individuals.
Conclusions:
- Isolation and expansion of Tregs are feasible in kidney transplant patients on immunosuppression.
- Autologous Treg cell infusion is safe and well-tolerated.
- Further trials are warranted to evaluate Treg efficacy in treating kidney transplant inflammation.
Related Concept Videos
01:26Kidney Transplant II: Surgical Procedure
537
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
537
01:16Kidney Transplant III: Nursing Management
442
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
442
01:28Kidney Transplant I: Introduction
586
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
586
01:24T Cell Types and Functions
2.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.8K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
652
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
652
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K